Xermelo Approval History
FDA Approved: Yes (First approved February 28, 2017)
Brand name: Xermelo
Generic name: telotristat ethyl
Dosage form: Tablets
Company: Lexicon Pharmaceuticals, Inc.
Treatment for: Carcinoid Syndrome Diarrhea
Xermelo (telotristat ethyl) is an oral tryptophan hydroxylase inhibitor indicated for use in combination with somatostatin analog (SSA) therapy for the treatment of carcinoid syndrome diarrhea in patients with metastatic neuroendocrine tumors.
Development History and FDA Approval Process for Xermelo
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.